HLS THERAPEUTICS INC (HLS.CA) Stock Fundamental Analysis
Canada - TSX:HLS - CA40390B1094 - Common Stock
5.29 CAD
-0.03 (-0.56%)
Overall HLS gets a fundamental rating of 3 out of 10. We evaluated HLS against 31 industry peers in the Pharmaceuticals industry. HLS has a bad profitability rating. Also its financial health evaluation is rather negative. HLS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year HLS has reported negative net income.
HLS had a positive operating cash flow in the past year.
In the past 5 years HLS always reported negative net income.
HLS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
HLS's Return On Assets of -10.09% is in line compared to the rest of the industry. HLS outperforms 45.16% of its industry peers.
HLS has a Return On Equity (-22.60%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.09% | ||
| ROE | -22.6% | ||
| ROIC | N/A |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HLS's Gross Margin of 82.59% is amongst the best of the industry. HLS outperforms 100.00% of its industry peers.
HLS's Gross Margin has declined in the last couple of years.
HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
HLS has less shares outstanding than it did 1 year ago.
HLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HLS has been reduced compared to a year ago.
2.2 Solvency
HLS has an Altman-Z score of -0.76. This is a bad value and indicates that HLS is not financially healthy and even has some risk of bankruptcy.
HLS has a Altman-Z score of -0.76. This is comparable to the rest of the industry: HLS outperforms 51.61% of its industry peers.
HLS has a debt to FCF ratio of 4.74. This is a neutral value as HLS would need 4.74 years to pay back of all of its debts.
The Debt to FCF ratio of HLS (4.74) is better than 80.65% of its industry peers.
A Debt/Equity ratio of 0.74 indicates that HLS is somewhat dependend on debt financing.
HLS has a Debt to Equity ratio of 0.74. This is in the lower half of the industry: HLS underperforms 70.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 4.74 | ||
| Altman-Z | -0.76 |
ROIC/WACCN/A
WACC7.66%
2.3 Liquidity
HLS has a Current Ratio of 1.09. This is a normal value and indicates that HLS is financially healthy and should not expect problems in meeting its short term obligations.
HLS's Current ratio of 1.09 is on the low side compared to the rest of the industry. HLS is outperformed by 77.42% of its industry peers.
A Quick Ratio of 0.84 indicates that HLS may have some problems paying its short term obligations.
HLS has a worse Quick ratio (0.84) than 74.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.00% over the past year.
The Revenue has decreased by -4.20% in the past year.
The Revenue has been growing slightly by 0.88% on average over the past years.
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-2.4%
3.2 Future
HLS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.68% yearly.
The Revenue is expected to grow by 4.84% on average over the next years.
EPS Next Y47.87%
EPS Next 2Y33.72%
EPS Next 3Y23.91%
EPS Next 5Y16.68%
Revenue Next Year0.81%
Revenue Next 2Y5.6%
Revenue Next 3Y4.03%
Revenue Next 5Y4.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HLS. In the last year negative earnings were reported.
Also next year HLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HLS is valued a bit cheaper than 67.74% of the companies in the same industry.
80.65% of the companies in the same industry are more expensive than HLS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10 | ||
| EV/EBITDA | 10.54 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HLS's earnings are expected to grow with 23.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.72%
EPS Next 3Y23.91%
5. Dividend
5.1 Amount
No dividends for HLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:HLS (11/10/2025, 7:00:00 PM)
5.29
-0.03 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.72%
Inst Owner ChangeN/A
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap165.47M
Revenue(TTM)56.42M
Net Income(TTM)-15.04M
Analysts77.78
Price Target6.83 (29.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.14%
Min EPS beat(2)-27.3%
Max EPS beat(2)-16.97%
EPS beat(4)0
Avg EPS beat(4)-14.64%
Min EPS beat(4)-27.3%
Max EPS beat(4)-2.42%
EPS beat(8)1
Avg EPS beat(8)-31.91%
EPS beat(12)1
Avg EPS beat(12)-51.17%
EPS beat(16)2
Avg EPS beat(16)-42.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.71%
Min Revenue beat(2)-3.24%
Max Revenue beat(2)-0.17%
Revenue beat(4)0
Avg Revenue beat(4)-2.79%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)-0.17%
Revenue beat(8)1
Avg Revenue beat(8)-4.15%
Revenue beat(12)2
Avg Revenue beat(12)-4.33%
Revenue beat(16)2
Avg Revenue beat(16)-5%
PT rev (1m)0%
PT rev (3m)19.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.08 | ||
| P/FCF | 10 | ||
| P/OCF | 9.13 | ||
| P/B | 1.76 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.54 |
EPS(TTM)-0.68
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)0.53
FCFY10%
OCF(TTM)0.58
OCFY10.96%
SpS2.54
BVpS3
TBVpS-2.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.09% | ||
| ROE | -22.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.59% | ||
| FCFM | 20.79% |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 4.74 | ||
| Debt/EBITDA | 3.23 | ||
| Cap/Depr | 5.15% | ||
| Cap/Sales | 1.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 83.94% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.09 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | -0.76 |
F-Score6
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y47.87%
EPS Next 2Y33.72%
EPS Next 3Y23.91%
EPS Next 5Y16.68%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%-2.4%
Revenue Next Year0.81%
Revenue Next 2Y5.6%
Revenue Next 3Y4.03%
Revenue Next 5Y4.84%
EBIT growth 1Y44.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year289.34%
EBIT Next 3Y62.53%
EBIT Next 5Y37.49%
FCF growth 1Y-17.32%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-10.49%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%
HLS THERAPEUTICS INC / HLS.CA FAQ
Can you provide the ChartMill fundamental rating for HLS THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to HLS.CA.
Can you provide the valuation status for HLS THERAPEUTICS INC?
ChartMill assigns a valuation rating of 3 / 10 to HLS THERAPEUTICS INC (HLS.CA). This can be considered as Overvalued.
What is the profitability of HLS stock?
HLS THERAPEUTICS INC (HLS.CA) has a profitability rating of 2 / 10.
Is the dividend of HLS THERAPEUTICS INC sustainable?
The dividend rating of HLS THERAPEUTICS INC (HLS.CA) is 0 / 10 and the dividend payout ratio is 0%.